司来吉兰治疗帕金森病的临床疗效观察  

作　　者：翁秋燕[1] 张昀赟 胡巧霞[1] 王美华[1] 陈季志[1] 查芹[1] 

机构地区：[1]宁波大学医学院附属医院神经内二科,315000

出　　处：《浙江临床医学》2015年第2期208-210,共3页Zhejiang Clinical Medical Journal

摘　　要：目的观察司来吉林治疗帕金森病（PD）的临床有效性及安全性。方法采用开放性的自身治疗前后对照研究。对50例PD患者进行统一PD评分量表（UPDRS），10例患者直接给予司来吉兰治疗，40例患者在原药基础上加用司来吉兰治疗，疗程均为12周。予治疗后2、4、8、12周进行UPDRS评分评估治疗效果，同时评价安全性。安全性指标为实验室值、不良反应、心电图及血压。结果50例患者经过司来吉兰治疗，44例有效，有效率为88％（44／50）。50例患者用药后在UPDRS总评分，UPDRSⅠ精神、行为、情绪评分，UPDRSⅡ日常生活能力评分，UPDRSⅢ运动检查评分、震颤评分及肌强直评分，较用药前有不同程度的改善，其结果差异有统计学意义（P〈0．05）。治疗期间未见明显严重不良反应。结论司来吉兰有效改善PD患者的临床症状，副作用少，是一种安全有效的抗PD药物。Objective To study the clinical effect and safety of selegiline in the treatment of patients with Parkinson＇ s disease （ PD ） at the early and advanced stage. Methods The open-label self-control study was performed. Fifty patients with PD were treated with selegiline for 12 weeks and evaluated by Unified Parkinson＇ s disease Rating Scale （ UPDRS ） before and after the treatment. 10 of them were treated with selegiline only, while the rest 40 patients were treated with selegiline and other anti-PD drugs. All the 50 cases received follow-up at the week 2, 4, 8, 12 to evaluate the therapeutic effect. The laboratory indexes, adverse effects, electrocardiogram and the blood pressure were also observed to evaluate the safety of the selegiline. Results After the treatment, the symptoms of the PD patients were alleviated in 44 patients, with a total effective rate of 88%. The scores of UPDRS, mental symptoms （ UPDRS Ⅰ ） , daily activities （ UPDRS Ⅱ ） , motor function （ UPDRS Ⅲ） , trembling and myotonia were statistically significantly lower than those before selegiline treatment （ P〈0.05 ） .The adverse effects in selegiline treatment was mild. Conclusions It is proved that selegiline is a safe and effective drug for PD both at early and advanced stages.

关 键 词：司来吉兰 帕金森病 统一帕金森病评分量表 

分 类 号：R971[医药卫生—药品]